Stuttgart, Germany

Martin Siegemund

USPTO Granted Patents = 6 

 

 

Average Co-Inventor Count = 3.8

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2017-2024

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Martin Siegemund: A Pioneer in TNF Receptor Research

Introduction

Martin Siegemund, an accomplished inventor based in Stuttgart, Germany, has significantly contributed to the field of biochemistry through his innovative research and development. He holds a total of six patents, particularly focusing on tumor necrosis factor (TNF) receptors and their interactions, which have profound implications in therapeutic applications.

Latest Patents

Siegemund's latest inventions include:

1. **TNFR2 Agonists with Improved Stability** - This invention pertains to a polypeptide consisting of three TNF homology domains (THDs) that specifically bind to the extracellular portion of TNFR2. The polypeptides exhibit enhanced stability due to specific amino acid linkages and peptide linkers, allowing for improved functionality. It also encompasses polypeptide multimers that comprise several of these polypeptides, enhancing their therapeutic potential.

2. **Tumor Necrosis Factor Receptor (TNFR) Binding Protein Complex with Improved Binding and Bioactivity** - This invention presents a TNFR binding protein complex that includes 12 or more N protein ligands specifically binding to the extracellular part of TNFR. It is particularly aimed at binding to TNFR2 and features polymerization domains, which enhance the binding effectiveness and biological activity of the complex.

Career Highlights

Martin Siegemund has had a remarkable career, contributing his expertise at the University of Stuttgart. His work in the field of TNF receptors has not only advanced scientific understanding but also opened new pathways for therapeutic development.

Collaborations

Throughout his career, Siegemund has collaborated with notable figures in the field, including Roland Kontermann and Klaus Pfizenmaier. These collaborations have been pivotal in propelling his research and enhancing the impact of his inventions.

Conclusion

With a strong portfolio of patents and a collaborative spirit, Martin Siegemund continues to be a pivotal figure in biochemistry, specifically in the study and application of TNF receptors. His innovations not only reflect his dedication as an inventor but also his commitment to advancing medical science for better therapeutic interventions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…